Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study by Domchek, Susan M, MD, Postel-Vinay, Sophie, MD, Im, Seock-Ah, Prof, Park, Yeon Hee, Prof, Delord, Jean-Pierre, Prof, Italiano, Antoine, Prof, Alexandre, Jerome, Prof, You, Benoit, MD, Bastian, Sara, MD, Krebs, Matthew G, MD, Wang, Ding, MD, Waqar, Saiama N, MBBS, Lanasa, Mark, MD, Rhee, Joon, PhD, Gao, Haiyan, PhD, Rocher-Ros, Vidalba, PhD, Jones, Emma V, PhD, Gulati, Sakshi, PhD, Coenen-Stass, Anna, PhD, Kozarewa, Iwanka, PhD, Lai, Zhongwu, PhD, Angell, Helen K, PhD, Opincar, Laura, PharmD, Herbolsheimer, Pia, MD, Kaufman, Bella, Prof

Get full text